Form 4: Director Robert Glassman Executes Pharvaris Stock Sale

Pharvaris N.V. Director Robert Glassman exercised stock options and sold 10,000 shares of common stock.

Summary

• Director Robert Glassman exercised options to acquire 5,333 shares of Pharvaris N.V. common stock at a price of $22.31 per share.
• Following the exercise, the director sold a total of 10,000 shares across two transactions on May 15, 2026.
• The sales were executed at weighted average prices of $29.8314 and $29.8167 per share.
• The director's direct beneficial ownership in Pharvaris N.V. decreased to 10,500 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine disclosure of insider equity management that does not signal a change in corporate strategy or financial health.

Positives

• The transaction reflects the exercise of vested stock options, indicating alignment with long-term equity compensation structures.

Negatives

• The director reduced their direct equity stake in the company by 10,000 shares.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term share price appreciation, though these transactions are often pre-planned.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions are common in the biotechnology sector as executives and directors manage their personal portfolios and exercise vested equity compensation. This activity is standard corporate governance and does not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The exercise and sale of shares by directors is a routine practice in the biopharmaceutical industry, consistent with standard executive compensation programs at companies like Ionis Pharmaceuticals or Alnylam Pharmaceuticals.

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents a standard exercise and sale of vested equity.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Director Transaction, Equity Compensation